IL312861A - Treatment of regional baldness - Google Patents

Treatment of regional baldness

Info

Publication number
IL312861A
IL312861A IL312861A IL31286124A IL312861A IL 312861 A IL312861 A IL 312861A IL 312861 A IL312861 A IL 312861A IL 31286124 A IL31286124 A IL 31286124A IL 312861 A IL312861 A IL 312861A
Authority
IL
Israel
Prior art keywords
compound
oxopropanenitrile
octan
pyrrolo
pyrimidin
Prior art date
Application number
IL312861A
Other languages
English (en)
Hebrew (he)
Original Assignee
Leo Pharma As
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2015190849A external-priority patent/JP2017066061A/ja
Application filed by Leo Pharma As, Japan Tobacco Inc filed Critical Leo Pharma As
Publication of IL312861A publication Critical patent/IL312861A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL312861A 2015-09-24 2016-09-22 Treatment of regional baldness IL312861A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15186644 2015-09-24
JP2015190849A JP2017066061A (ja) 2015-09-29 2015-09-29 円形脱毛症治療剤
PCT/EP2016/072531 WO2017050891A1 (en) 2015-09-24 2016-09-22 Treatment of alopecia areata

Publications (1)

Publication Number Publication Date
IL312861A true IL312861A (en) 2024-07-01

Family

ID=57047187

Family Applications (3)

Application Number Title Priority Date Filing Date
IL312861A IL312861A (en) 2015-09-24 2016-09-22 Treatment of regional baldness
IL298520A IL298520A (en) 2015-09-24 2016-09-22 Treatment of alopecia areata
IL257918A IL257918A (en) 2015-09-24 2018-03-06 Treatment of regional baldness

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL298520A IL298520A (en) 2015-09-24 2016-09-22 Treatment of alopecia areata
IL257918A IL257918A (en) 2015-09-24 2018-03-06 Treatment of regional baldness

Country Status (27)

Country Link
US (3) US20180263986A1 (enExample)
EP (1) EP3352734B1 (enExample)
JP (1) JP6776345B2 (enExample)
KR (1) KR102728341B1 (enExample)
CN (1) CN108135834B (enExample)
AU (3) AU2016325388A1 (enExample)
BR (1) BR112018005771B1 (enExample)
CA (1) CA2998972A1 (enExample)
CY (1) CY1122837T1 (enExample)
DK (1) DK3352734T3 (enExample)
ES (1) ES2779762T3 (enExample)
HR (1) HRP20200472T1 (enExample)
HU (1) HUE049052T2 (enExample)
IL (3) IL312861A (enExample)
LT (1) LT3352734T (enExample)
MX (1) MX375024B (enExample)
MY (1) MY196541A (enExample)
PL (1) PL3352734T3 (enExample)
PT (1) PT3352734T (enExample)
RS (1) RS60365B1 (enExample)
RU (1) RU2754997C2 (enExample)
SG (1) SG10202111361TA (enExample)
SI (1) SI3352734T1 (enExample)
TW (1) TWI720022B (enExample)
UA (1) UA124192C2 (enExample)
WO (1) WO2017050891A1 (enExample)
ZA (1) ZA201801722B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119367282A (zh) * 2019-12-27 2025-01-28 乐敦制药株式会社 水性组合物
WO2023029943A1 (zh) * 2021-09-03 2023-03-09 星药科技(北京)有限公司 一种芳杂环化合物及其制备方法和用途
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US8637569B2 (en) * 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤

Also Published As

Publication number Publication date
JP2018528238A (ja) 2018-09-27
SG10202111361TA (en) 2021-12-30
UA124192C2 (uk) 2021-08-04
LT3352734T (lt) 2020-04-10
RS60365B1 (sr) 2020-07-31
DK3352734T3 (da) 2020-03-30
ZA201801722B (en) 2025-06-25
AU2016325388A1 (en) 2018-03-29
EP3352734B1 (en) 2020-01-15
NZ740690A (en) 2024-11-29
ES2779762T3 (es) 2020-08-19
RU2754997C2 (ru) 2021-09-08
EP3352734A1 (en) 2018-08-01
IL298520A (en) 2023-01-01
SI3352734T1 (sl) 2020-07-31
BR112018005771B1 (pt) 2023-12-05
HUE049052T2 (hu) 2020-09-28
MY196541A (en) 2023-04-19
CA2998972A1 (en) 2017-03-30
CN108135834A (zh) 2018-06-08
US20180263986A1 (en) 2018-09-20
KR20180054767A (ko) 2018-05-24
AU2024204716B2 (en) 2026-06-11
AU2022202508A1 (en) 2022-05-12
HRP20200472T1 (hr) 2020-09-18
JP6776345B2 (ja) 2020-10-28
US20240398809A1 (en) 2024-12-05
RU2018114922A (ru) 2019-10-28
MX2018003332A (es) 2018-08-16
PL3352734T3 (pl) 2020-08-24
TWI720022B (zh) 2021-03-01
CN108135834B (zh) 2021-07-27
WO2017050891A1 (en) 2017-03-30
PT3352734T (pt) 2020-03-31
RU2018114922A3 (enExample) 2019-12-11
US20220088020A1 (en) 2022-03-24
BR112018005771A2 (pt) 2018-10-09
AU2024204716A1 (en) 2024-07-25
KR102728341B1 (ko) 2024-11-11
MX375024B (es) 2025-03-06
HK1257770A1 (en) 2019-10-25
TW201717955A (zh) 2017-06-01
IL257918A (en) 2018-05-31
CY1122837T1 (el) 2021-05-05

Similar Documents

Publication Publication Date Title
Gogas et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management
US20240398809A1 (en) Treatment of alopecia areata
JP2024516795A (ja) エベロリムスおよびアムセネストラントを含む組合せ物
UA100119C2 (uk) Застосування 3-альфа-андростандіолу в поєднанні з агоністом 5-ht1а для лікування сексуальної дисфункції
US20230138114A1 (en) Treatment of hand eczema
EP4251164A2 (en) Treatment of raynaud's disease
US20250275974A1 (en) Treatment of frontal fibrosing alopecia
HK1257770B (en) Treatment of alopecia areata
KR20160110963A (ko) 암 치료를 위한 pi3k 억제제를 포함하는 제약 조합물
WO2025085050A1 (en) Treatment of frontal fibrosing alopecia
HK40110657A (en) Cdk4 inhibitor for the treatment of cancer
EP4665725A2 (en) Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations